These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. LeWitt PA Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783 [TBL] [Abstract][Full Text] [Related]
13. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730 [TBL] [Abstract][Full Text] [Related]
14. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. Colzi A; Turner K; Lees AJ J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668 [TBL] [Abstract][Full Text] [Related]
15. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
17. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Bennett JP; Landow ER; Schuh LA Neurology; 1993 Aug; 43(8):1551-5. PubMed ID: 8043043 [TBL] [Abstract][Full Text] [Related]
18. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Grant SM; Heel RC Drugs; 1991 Jun; 41(6):889-926. PubMed ID: 1715266 [TBL] [Abstract][Full Text] [Related]